Print Page  Close Window

Investor Relations
Corporate Profile
Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning. ... More >>
Latest PresentationsMore >>
Title
Download Documentation Zogenix July 2015 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$19.87
Change (%) Stock is Down 0.4 (1.97%)
Volume410,265
Data as of 07/27/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
07/07/15Zogenix to Host Key Opinion Leader Meeting Tuesday, July 14, in New York City
SAN DIEGO, July 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader breakfast focused on Dravet syndrome, including an overview of ZX008, the Company's investigational proprietary pediatric formulation of low-dose fenfluramine, which is designated as an orphan drug for the treatment of Dravet syndrome in ... 
Printer Friendly Version
07/06/15Zogenix Expands Senior Leadership Team to Further Drive Strategic Focus on CNS Disorders and Orphan Drug Development
Company Appoints Dr. Gail Farfel as Chief Development Officer and Dr. Thierry Darcis as General Manager, Europe SAN DIEGO, July 6, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today the appointments of Gail M. Farfel, Ph.D., as Executive Vice President and Chief Development Officer, and Thierry Darcis, M.D., M.B.A., as Executive Vice President and Gene... 
Printer Friendly Version
07/06/15Zogenix to Participate in Cantor Fitzgerald Healthcare Conference
SAN DIEGO, July 6, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Cantor Fitzgerald Healthcare Conference in New York, NY, on July 8, 2015. Cantor Fitzgerald Healthcare Conference Date: Wednesday, July 8, 2015 ... 
Printer Friendly Version
06/18/15Zogenix Announces Shareholders and Board of Directors Approve Reverse Stock Split
SAN DIEGO, June 18, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that at the annual general meeting of shareholders held earlier today, shareholders voted to approve a proposal authorizing the board of directors of the Company to amend the Company's certificate of incorporation to effect a reverse stock split of Zogenix's outstanding common shares... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.